Preventing the cell’s protein factories from making the notorious cancer-causing protein MYC could stop out-of-control tumors.
BioMarin’s Roctavian, once forecast to sell $50M to $150M last year, only pulls in a fraction of that
In April, BioMarin forecast that its new gene therapy Roctavian would bring in $50 million to $100 million in sales by the end of 2023. Instead,
February 24, 2024